Introduction
To date, human anti-tumor vaccination has not delivered on its promises. Reasons for failure include tumor immune escape mechanisms, limited availability of tumor speci®c antigens, as well as failure to deliver tumor antigens in the right immunological context. Progress in molecular biology and immunology has provided technologies to detect an ever increasing choice of new tumor speci®c antigens. One of the most important questions remains the delivery of these tumor antigens in an eective way to the immune system of a cancer patient. This task is performed under normal circumstances by dendritic cells (DCs) . DCs are sentinels of the immune system located at sites of antigen entry such as skin. They take up antigen and carry it to secondary lymphoid organs. They are highly specialized antigen-presenting cells (APCs) for the activation of speci®c eector T cells recirculating in secondary lymphoid organs. In the past years an enormous increase in our understanding of DC biology has opened new ways for the application of these cells for immunotherapy of cancer.
The DC family of antigen-presenting cells
The family of human DC displays considerable heterogeneity and plasticity at the level of phenotype and function . DC may derive from two potential lineages: myeloid or lymphoid ( Figure 1 ). Myeloid progenitors give rise to two main precursors: CD14+CD11c+ precursors and CD147CD11c+ precursors (Caux et al., 1996) . CD14+CD11c+ cells dierentiate in the presence of IL-4 and GM-CSF into interstitial dendritic cells which correspond to dermal dendritic cells in vivo (Grassi et al., 1998) . In the presence of M-CSF, CD14+CD11c+ precursor cells acquire characteristics of macrophages. CD11c+ DC may be also reverted to macrophages under the same conditions. CD147CD11c+ precursors yield DC of the Langerhans cell type in response to GM-CSF, IL-4 and TGF-beta. Immature dermal or Langerhans type DC correspond to tissue resident sentinels in peripheral tissue sites. Upon encounter of T cell derived signals such as CD40L or microbial products such as LPS, they might be further driven along their dierentiation pathway into so-called mature DC. Mature DC correspond to interdigitating DC in T cell areas of lymph nodes and marginal zone of spleen with stable phenotype and function. Immature DC are highly endocytic cells, specialized for sampling antigens in the periphery, while mature DC are optimized for presentation of antigens to eector T cells (Figure 2 ). They have low endocytic capacity and express high levels of adhesion, co-stimulatory and MHC molecules as well as chemokine receptors necessary for migration to secondary lymphoid tissues. Markers of mature DC are CD83, DC-LAMP and p55. A third major subset of DC with a presumed lymphoid origin are C147CD11c-IL-3Ra+ DC precursors (also called pDC2, plasmacytoid T cell or IFNalpha producing cell) (Grouard et al., 1997) . These cells depend on IL-3 as survival factor and may be matured through CD40 signaling. Further surface markers include CD45RA and ILT-3 (Cella et al., 1999) . They display low phagocytic activity and are the major source of IFN ± a production in response to viral infection (Siegal et al., 1999) while CD11c+ cells are major sources of response to the bacterial product LPS. Mature DC2 may eectively polarize T helper responses towards production of TH-2 type cytokines (Rissoan et al., 1999) . This polarization might depend on the maturity of DC2.
DC and cancer
Early data suggestive for a role of DC in tumor defense were based on studies in experimental animals, or on quanti®cation of DC in the tumor areas and comparison to the clinical outcome of the patient. When normal syngeneic DC were given to mice with palpable tumors, tumor regression or delay in tumor growth was obtained (Knight et al., 1985) . The same study suggested that DC pulsed with low doses of tumor antigen elicited an immune response, while high doses of antigen blocked them. In animal vaccination studies with irradiated tumor cells, retrovirally transfected with granulocyte-macrophage colony sti-mulating factor (GM-CSF), speci®c and long lasting tumor immunity was obtained, and partially attributed to the in¯ux of DC to the vaccination site, as well as their activation through locally secreted GM-CSF (Drano et al., 1993) . Eectiveness of DC vaccination in the induction of an eector T cell response able to protect against tumor growth was directly demonstrated in several mouse models (Flammand et al., 1993; Grabbe et al., 1991; Mayordomo et al., 1995; Porgador and Gilboa, 1995; Zitvogel et al., 1996) . Early studies were performed with crude preparations of splenocytes or epidermal cells pulsed with tumor lysate. Later studies used de®ned techniques to generate large numbers of DCs in vitro from murine bone marrow cultures supplemented with GM-CSF plus IL-4. Signi®cant anti-tumor responses were obtained with DCs pulsed with de®ned peptides, acid-eluted peptides from tumor cells as well as proteins. Even in the case of already established tumors DC vaccination was able to be of therapeutic bene®t. A further strategy is to expand DCs in vivo through administration of fms-like tyrosine kinase 3 (FLT-3) ligand or FLT-3 cytokine fusion proteins. It results in preferential mobilization of DC precursors from the bone marrow. Studies using FLT-3 ligand to expand DC precursors have shown to protect mice from tumor growth and might be improved by adding CD40 ligand (Borges et al., 1999) . Animal studies provided the proof of principle for antigen-pulsed DC vaccination against cancer but suer from several draw backs. These models systems are highly arti®cial using inbred animals with fast growing tumors, not re¯ecting the situation in humans where tumors develop in the presence of a functional immune system, shaping or editing the tumor. Furthermore, model tumors used in mice are often highly immunogenic, and foreign proteins are used to induce an antigen speci®c response. Innumerable mice have been protected or cured from cancer with a variety of strategies, but rarely these approaches were successfully translated to humans.
In humans early immunohistochemical studies on the presence of DC in tumors were mainly done on the Langerhans type of DCs (Langerhans cells, LC) identi®ed by anti-CD1a antibodies. These cells are reduced in conditions which are known to parallel a higher incidence of skin tumors such as chronically sun exposed skin or aging skin. In melanocytic tumors of the skin, the number of DC seems to be reduced within the epidermis overlying invasive melanomas. Furthermore cells with a epidermal DC phenotype are present within the in®ltrate surrounding melanomas (BroÈ cker et al., 1982) . In non-melanocytic tumors of the skin such as basal cell carcinoma or squamous cell carcinoma, DCs are present but con¯icting data exist if DC numbers are reduced or increased in these tumors (Nestle and Nickolo, 1994) . Several histological studies in human cancers like squamous cell carcinoma of the esophagus, colorectal adenocarcinoma, papillary thyroid carcinoma, gastric carcinoma, and recently lung carcinoma suggested that patients with high numbers of DC present in the tumor survived longer than patients with few or no DC in the tumor (Becker, 1993) . There is also mounting evidence that dendritic cell expression of co-stimulatory molecules, maturation and antigen presenting function might be subverted by the tumor (Almand et al., 2000; Bell et al., 1999; Enk et al., 1997; Gabrilovich et al., 1996; Nestle et al., 1997) .
DC sources
The addition of DCs to our choices of adjuvants for immunotherapy of cancer has been possible due to the introduction of new methods to isolate and generate DCs. Early techniques relied on properties of DCs such as non-adherence to plastic, low density on bovine serum albumin (BSA) or metrizamide gradients and absence of expression of T cell, B cell, NK cell or macrophage lineage markers (Freudenthal and Steinman, 1990 ). These techniques are cumbersome to perform, time consuming and yield very low numbers of DCs making it impossible to move into a clinical application. A breakthrough was achieved after the discovery that DCs might be generated from peripheral monocytes or CD34 bone marrow precursors in the presence of certain cytokines such as GM-CSF, IL-4 and TNF-a (Caux et al., 1992; Inaba et al., 1992; Romani et al., 1994; Sallusto and Lanzavecchia, 1994) . These DCs are potent APCs fully equipped with the necessary HLA and accessory molecules to drive T cell proliferation. The physiological counterpart of monocyte derived DC (MoDC) are located in a perivascular manner in human dermis, so-called dermal DC (DDC) (Grassi et al., 1998) . CD34 derived DC develop along two major dierentiation pathways: one leading to Birbeck granule positive Langerhans cells (LC), while the other major pathway generates DDC (see above). Both cell subsets might be used for immunotherapy. Further maturation and modi®cation of DC is obtained by adding stimuli such as monocyte conditioned supernatant, cytokine cocktails (including IL-1, IL-6 and TNF-a) or CD40L (Figure 2 ). In ongoing immunotherapy protocols, DC are either generated from immature circulating blood precursors or by in vitro culture of monocytes or CD34 progenitor cells. Currently the major sources of DC for immunotherapy are: (i) CD34 cells cultured in complex cytokine cocktails including SCF, IL-3, IL-6, IL-4, GM-CSF (Mackensen et al., 2000b) ; (ii) monocyte derived DCs cultured in IL-4, GM-CSF (+/7 further maturation stimuli) and (iii) blood derived DC obtained through a modi®ed gradient method (Burch et al., 2000) .
Critical issues for optimal DC vaccination
Apart from choosing the right source of DC, critical issues for successful vaccination involve choice of antigen, antigen loading, route and schedule of administration, as well as immuno-monitoring. A wide range of antigenic preparations are available for loading of DC. Peptide antigens are well de®ned antigenic epitopes binding to a de®ned set of MHC molecules, produced under good manufacturing practice (GMP) conditions and easily accessible for immuno-monitoring of a peptide speci®c T cell response. They require however analysis of the MHC background of patients, the knowledge of the sequence of the relevant peptide epitope and are prone to development of tumor antigen escape variants. The use of whole protein antigens, DNA, RNA or recombinant viruses encoding the antigen of choice allows host HLA molecules to select the appropriate peptide epitope for presentation as peptide-MHC complex on the cell surface. This approach does not require analysis of MHC molecules. One has to be aware though, that the spectrum of epitopes seen by eector T cells might be restricted, since certain peptides are not presented by DC due to missing processing at the level of the proteasome (Morel et al., 2000) . Ineective cross-presentation of large protein antigens, low transfection eciency using cDNA or RNA and dicult immuno-monitoring of an antigen speci®c response are further points to consider. Recently, there is a renaissance of using the entire antigenic content of a tumor cell for vaccination to present as many tumor antigens as possible to the immune system and minimize the occurrence of immune escape variants. This might be achieved by either pulsing DC with tumor lysate or tumor derived RNA, apoptotic bodies or fusion of tumor cells and DCs Shimizu et al., 1999) . This approach is not restricted by MHC molecules but by the availability of tissue serving as a source of tumor lysate or tumor derived RNA. Often skin metastases are the only easily available source of tumor material. It has to be kept in mind that these patients tend to respond better to immunotherapy and therefore a bias in choosing patients with better prognosis might be introduced through selection of patients with skin metastases. Several groups are currently trying to optimize delivery of tumor fragments or lysates to DC (e.g. induction of apoptotic bodies) to maximize cross-presentation and stimulation of DC (Nouri-Shirazi et al., 2000) . Representative tumor RNA might be also obtained from frozen tissue specimens using microdissection technology in combination with RNA ampli®cation methods . These antigens might include shared tumor antigens such as telomerase . Again, a major disadvantage in using whole tumor in form of lysates, apoptotic bodies or RNA is that measuring eector cells in vitro and in vivo is dicult to achieve.
After pulsing with tumor antigen, DC need to be administered in an eective way to the cancer patient. Several possible injection modes may be envisaged, such as intravenous, intradermal, subcutaneous or intranodal injection. A combination of intravenous and intradermal injection has been used in one published trial. Interestingly, antigen speci®c immune response measured by Elispot assay was induced after intradermal injection but decreased after i.v. injection (Thurner et al., 1999 ). An explanation might be that DC injected i.v. were trapped in the lung leading to disruption of DC antigen complexes. Free antigen may disseminate in the body and may be presented in the wrong immunologic context leading to induction of T cell de-activation instead of activation. Intradermal or subcutaneous injection seems to be an appropriate method if we extrapolate data obtained from animal models (Schreurs et al., 2000) . Intracutaneously injected DC are supposed to migrate through the aerent lymphatics to a tissue draining lymph node (Eggert et al., 1999) . Migratory capacity and also the number of DC which ®nally reach the lymph node in an active T cell stimulatory mode will be a critical issue for future studies. Since convincing data about the migratory capacity of human DCs are dicult to obtain, we developed in 1993 the concept to inject our DC preparation directly under ultrasound control in a normal appearing inguinal lymph node (Nestle et al., 1998) . As discussed above the lymph node is the appropriate meeting point for a DC-T cell cross talk and is at least from a theoretical point of view the preferred injection site for antigen loaded DC.
Oncogene Dendritic cell vaccination for cancer FO Nestle Detection of an antigen speci®c immune response is an important surrogate marker to control for an eective vaccination strategy even though correlation with clinical response will be the most important issue. The classic way to detect CTL activity is measurement of lytic activity against 51 Cr labeled target cells. Since precursor frequencies are low, in vitro re-stimulations are often necessary in order to reach a CTL frequency detectable by cytotoxicity assays. These techniques are time consuming and may introduce an artefact which limits quantitative analysis. Still, this method is the gold standard since it measures lytic activity of eector cells, the same functional activity one would like to induce in vivo. Recently introduced methods rely on measurement of release of cytokines by CTL after contact with antigen (Romero et al., 1998) . Cytokines may be measured by an ELISA method (ELISPOT) or quanti®ed by intracellular cytokine staining and detection by¯ow cytometry. Detection of cytokine release does not necessarily correlate with the cytolytic activity of a given cell. An additional method is delayed type hypersensitivity (DTH) testing for peptide speci®c immune responses. Peptide DTH testing has been successfully used in various mouse models and recruitment of peptide speci®c T cells to the injection site was demonstrated in humans (Nestle et al., 1998) . Peptide alone or DC pulsed with peptide are injected intradermally and induration as well as erythema is read after 48 h. This technique is easy to perform even though objective read out might be a problem and is observer dependent. DTH reactions are of importance for both the patient and the physician in charge since they can immediately suggest a successful induction of an antigen speci®c immune response. HLA-peptide tetrameric complexes is another tool for detection of an antigen speci®c immune response. A biotinylation site is introduced in in vitro synthesized MHC-peptide complexes. After biotinylation, tetramer formation is induced by adding¯uorescent labeled streptavidin. These complexes bind to antigen speci®c T cells which may be identi®ed on a per cell basis by¯ow cytometry. Tetramers may not be able to detect low or intermediate anity T cells which are of importance especially in the context of vaccination against self antigens (dierentiation antigens in melanoma).
DC clinical trials
For a given tumor to be eligible for DC vaccination, tumor antigen has to be available for loading on DC. This might be either achieved by loading de®ned antigens such as peptides or whole antigenic preparations such as tumor lysate or RNA on DC (Timmerman and Levy, 1999) . Numerous trials are currently ongoing or planned in the very fast moving ®eld of DC immunotherapy trials (Fong and Engleman, 2000) . For the sake of clarity, we will focus in the following only on published trials in DC vaccination which includes malignant melanoma, renal cell cancer, non-hodgkin lymphoma, multiple myeloma and prostate cancer (Table 1) . First preliminary data on the eciency of antigen-presenting cells such as GM-CSF stimulated monocytes injected intradermally were obtained in melanoma patients. Induction of MAGE-1 MHC class I restricted peptide speci®c CTL were induced by vaccination which also recognized autologous melanoma cells, however in the absence of signi®cant clinical response (Hu et al., 1996; Mukherji et al., 1995) . A pilot study using idiotype protein pulsed DC generated from circulating DC precursors (Markowicz and Engleman, 1990) was performed in four patients with malignant B cell lymphoma who had failed conventional chemotherapy. Induction of idiotype protein speci®c immune response was observed as well as complete clinical regression in two out of four patients (Hsu et al., 1996) . One patient remained in complete remission for more than 3 years (Fong and Engleman, 2000) . The ®rst trial using monocyte derived dendritic cells pulsed with peptide or tumor lysate in 16 patients with advanced metastatic melanoma re¯ected our experience with DC vaccination in the planning phase since 1993, with ®rst patients enrolled in 1996. Objective clinical responses were obtained in ®ve out of 16 patients including two complete and three partial remissions. Tumor regression occurred in skin, soft tissue, lung and pancreas indicating an impact on the clinical course of metastasizing melanoma. One CR is still ongoing while the other relapsed but has now a survival of 42 months. One PR developed CR after repeated vaccination and is now alive for 39 months. Induction of immune response was demonstrated by peptide speci®c DTH reactions including proof of recruitment of antigen speci®c CTL to the DTH challenge site. In 10 out of 10 HLA A2 positive patients peptide speci®c CTL were induced after the ®rst vaccination cycle (submitted for publication). Further trials were conducted in advanced melanoma using DC matured in a monocyte conditioned supernatant. Eective induction of peptide speci®c CTL was obtained in the absence of objective clinical response (Thurner et al., 1999) . A trial using CD34 derived DC matured with TNF-a, injected i.v. in 14 patients with advanced melanoma showed tumor regression in two patients, DTH reactions in four patients and expansion of peptide speci®c CTL in one patient (Mackensen et al., 2000b) . In multiple myeloma patients who have undergone peripheral stem cell rescue following ablative chemotherapy DCs were loaded with myeloma speci®c immunoglobulin idiotypes puri®ed from serum and injected into the patients. Two out of 12 patients developed an idiotype-speci®c cellular proliferative immune response and one of three patients studied developed a transient but idiotype-speci®c CTL response (Reichardt et al., 1999) . Studies in prostate cancer were performed using monocyte-derived DCs pulsed with peptides derived from prostate-speci®c membrane antigen (PSMA) in combination with radiotherapy and hormonal therapy. Thirty-three patients were treated, six partial and two complete responders were identi®ed by declining serum marker levels as well as immunological responses (Lodge et al., 2000; Murphy et al., 1999) . A further study was conducted in 13 patients suering from progressive hormone-refractory metastatic prostate carcinoma (Burch et al., 2000) . DC were generated from circulating blood precursors similar to the method introduced by Engleman et al. (Markowicz and Engleman, 1990 ) and pulsed with a fusion protein consisting of human granulocyte/macrophage-colony stimulating factor (GM-CSF) and human prostatic acid phosphatase (PAP). Two injections were per-formed 1 month apart. Circulating prostate-speci®c antigen levels dropped in three patients. T cells, drawn from patients after infusions, but not before, could be stimulated in vitro by PAP.
No signi®cant side eects using DC vaccination have been reported to date. We followed 30 advanced melanoma patients treated with peptide or tumor lysate pulsed DC (M Gilliet and FO Nestle, submitted) . In few patients there was slight fever after vaccination or painful lymph nodes. Since peptide antigens derived from melanocytic dierentiation antigens were used, autoimmune like reactions may occur. Progressive vitiligo especially in tumor lysate treated patients, as well as depigmentation of melanocytic nevi was observed during vaccination. No serious destructive autoimmunity was observed except the rare induction of anti-thyroid receptor autoantibodies as well as anti-nuclear antibodies.
One study reported the occurrence of an anaphylactoid reaction towards bovine proteins in the presence of detectable levels of IgE antibodies (Mackensen et al., 2000a) . In our as well as other studies (M Thurnher personal communication) no evidence of immediate type reactions was detected in skin test reactions. An explanation for IgE mediated immediate type reactions might be the usage of a special type of DC which induce an IgE favoring TH-2 type cytokine response.
Future directions
Proof of concept studies have now been performed in a variety of cancers in mice and men that demonstrate the unique capacity of DC as adjuvants for cancer immunotherapy. Immunological responses were obtained towards MHC class I and II antigens. Clinical responses including durable complete responses have been also achieved. The challenge of the future will be to extend these early results to a well de®ned and reproducible vaccination strategy according to current standards of good clinical practice. The history of cell therapy in the treatment of cancer has demonstrated that this is a dicult endeavor. Only the concerted eorts of academic centers, regulatory authorities and pharmaceutical industry will be able to drive this expensive development process.
Future research issues might involve the in vivo expansion of DC using speci®c growth factors such as FLT-3L, or growth factor cytokine fusion proteins (FLT-3L/G-CSF). Ideally, immunostimulatory DCs would be expanded in vivo without the necessity to manipulate them in vitro. Injection of antigens would then be presented in the optimal adjuvant context. However, current expansion protocols lead to proliferation and dierentiation of a variety of APCs including potentially tolerogenic subsets. Further research will hopefully lead to ®ne tuning of in vivo DC expansion protocols. Expressing antigens under the control of a DC promoter during DNA vaccination or attaching DC speci®c ligands to tumor antigens might be a way for in vivo targeting to the immunostimulatory DC compartment. In every antigen speci®c approach synergies with other therapeutic modalities should prevent occurrence of immune escape and improvement of patient outcome. Addition of IFN-a will increase among other eects the presentation of tumor antigens. IL-2 will have a co-stimulatory eect (Shimizu et al., 1999) . Even combinations with cytotoxic chemotherapy based combination therapies might be envisaged.
The brightest future will be in the combination of antigen speci®c immunotherapy with target oriented molecular therapies (e.g. using small molecule inhibitors of signal transduction or cell cycle proteins in tumor cells). The basis will be an extensive molecular pro®ling of tumor cells in a given cancer patient leading to an individualized highly eective multitarget therapy with low side eect pro®les. For this future to come true clinically oriented immunotherapists as well as molecular therapists still have a long way to go. 
